3-环戊氧基-4-甲基苯甲酰氯 | 144036-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-环戊氧基-4-甲基苯甲酰氯
• 英文名称: 3-cyclopentyloxy-4-methoxy benzoic acid chloride
• 英文别名: 3-(cyclopentyloxy)-4-methoxybenzoyl chloride；3-cyclopentyloxy-4-methoxybenzoyl chloride；4-methoxy-3-cyclopentyloxybenzoic acid chloride；3-cyclopentyloxy-4-methoxy benzoyl chloride；3-cyclopentyloxy-4-methoxybenzoic acid chloride；3-cyclopentyloxy-4-methoxy-benzoyl chloride
• CAS: 144036-19-1
• 化学式: C₁₃H₁₅ClO₃
• 分子量: 254.713
• InChiKey: OWWHXPWJCDTADU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

SDS

Name:	3-(Cyclopentyloxy)-4-methoxybenzoyl chloride Material Safety Data Sheet
Synonym:	None Known
CAS:	144036-19-1

Section 1 - Chemical Product MSDS Name:3-(Cyclopentyloxy)-4-methoxybenzoyl chloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
144036-19-1	3-(Cyclopentyloxy)-4-methoxybenzoyl ch	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 14 29 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Reacts violently with water. Contact with water liberates toxic gas.
Causes burns.Water-reactive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Water Reactive. Material will react with water and may release a flammable and/or toxic gas.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. DO NOT USE WATER! Contact professional fire-fighters immediately.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation. Do not expose spill to water.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not allow water to get into the container because of violent reaction. Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale.
Use and store under nitrogen. Use only in a chemical fume hood.
Discard contaminated shoes. Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Water free area. Store protected from moisture.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use explosion-proof ventilation equipment. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Exposure Limits CAS# 144036-19-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 45 - 47 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H15ClO3
Molecular Weight: 254.72

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures. Combines vigorously or explosively with water. Reacts with water to form hydrogen chloride, a toxic and corrosive gas.
Conditions to Avoid:
Incompatible materials, dust generation, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, amines, ammonia, water.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 144036-19-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Cyclopentyloxy)-4-methoxybenzoyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, WATER-REACTIVE, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: II
IMO
Shipping Name: CORROSIVE SOLID, WATER-REACTIVE, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE SOLID, WATER-REACTIVE, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 14 Reacts violently with water.
R 29 Contact with water liberates toxic gas.
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 144036-19-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 144036-19-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 144036-19-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-环戊氧基-4-甲基苯甲酰氯 在 ammonium hydroxide 作用下， 生成 3-(环戊基氧基)-4-甲氧基苯甲酰胺
  参考文献：
  名称：

  Compounds containing phenyl linked to aryl or heteroaryl by an

  摘要：

  这项发明涉及苯基化合物的药用，这些化合物通过各种连接与芳基团相连，用于抑制肿瘤坏死因子。该发明还涉及这些化合物、它们的制备以及含有这些化合物的药物组合物。此外，这项发明还涉及这些化合物的药用，用于抑制环状AMP磷酸二酯酶。

  公开号：

  US05679696A1
• 作为产物：
  描述：

  3-环戊氧-4-甲氧基苯甲醛 在 sodium hypochlorite 、 氯化亚砜 、 氨基磺酸 、 溶剂黄146 作用下， 反应 3.5h， 生成 3-环戊氧基-4-甲基苯甲酰氯
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Modeling of New 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-Dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) Related Phosphodiesterase 4D (PDE4D) Inhibitors

  摘要：

  A new series of 3-(cyclopentyloxy)-4-methoxyphenyl derivatives, structurally related to our hit GEBR-4a (1) and GEBR-7b (2), has been designed by changing length and functionality of the chain linking the catecholic moiety to the terminal cycloamine portion. Among the numerous molecules synthesized, compounds 8, 10a, and 10b showed increased potency as PDE4D enzyme inhibitors with respect to 2 and a good selectivity against PDE4A4, PDE4B2, and PDE4C2 enzymes, without both cytotoxic and genotoxic effects. The ability to enhance cAMP level in neuronal cells was assessed for compound 8. SAR considerations, also confirmed by in silico docking simulations, evidenced that both chain and amino terminal function characterized by higher hydrophilicity are required for a good and selective inhibitor-catalytic pocket interaction.

  DOI：

  10.1021/jm500855w

文献信息

• MEDICINAL COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1402900A1

  公开（公告）日：2004-03-31

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制破骨细胞活化的药剂，以及一种包含p38 MAP激酶抑制剂和/或TNF-α产生抑制剂的破骨细胞形成抑制剂。
• CONCOMITANT DRUGS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1354603A1

  公开（公告）日：2003-10-22

  The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

  本发明涉及一种含有一种或多种p38 MAP激酶抑制剂和/或TNF-α产生抑制剂以及从（1）非甾体抗炎药、（2）疾病修饰性抗风湿药、（3）抗细胞因子药物、（4）免疫调节剂、（5）类固醇和（6）c-Jun N末端激酶抑制剂中选择的一种或多种药物的药物制剂。这种组合药剂可用作预防或治疗风湿病、关节炎等疾病以及其他疾病的药物。
• Nitrogenous heterocyclic derivatives and medicine thereof
  申请人：Eisai Co., Ltd.

  公开号：US06352989B1

  公开（公告）日：2002-03-05

  The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same. wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents (a) a saturated hydrocarbon ring, (b) an unsaturated hydrocarbon ring, (c) a saturated heterocyclic ring or (d) an unsaturated heterocyclic ring, all of which may have a substituent group.

  本发明提供了一种新型的含氮杂环化合物，该化合物作为磷酸二酯酶-4抑制剂是有用的，以及包含该化合物的药物。此外，本发明还提供了一种由下列公式表示的含氮杂环化合物，其盐或水合物，以及包含它们的药物。 其中，环A是可以含有杂原子的芳香烃环，环B代表（a）饱和烃环，（b）不饱和烃环，（c）饱和杂环或（d）不饱和杂环，所有这些都可能含有取代基团。
• Synthesis of novel 1,2,4-oxadiazoles and analogues as potential anticancer agents
  作者：Dalip Kumar、Gautam Patel、Angela K. Chavers、Kuei-Hua Chang、Kavita Shah

  DOI：10.1016/j.ejmech.2011.03.031

  日期：2011.7

  A library of 3,5-disubstituted-1,2,4-oxadiazoles 7–9 and their bioisosters, 1,3,4-oxadiazole 14 and 1,3,4-thiadiazole 16, were synthesized and evaluated in vitro for their anticancer potential against a panel of six human cancer cell lines. The key step in the synthesis of oxadiazoles 7–9 involve coupling of amidoxime 6 with an appropriate carboxylic acid followed by thermal cyclization. The bioisosteres

  合成了3,5-二取代-1,2,4-恶二唑7–9及其生物等效物1,3,4-恶二唑14和1,3,4-噻二唑16的文库，并对其体外抗癌性进行了评估。对一组六种人类癌细胞系的潜力。合成恶二唑7–9的关键步骤包括将of胺肟6与适当的羧酸偶联，然后进行热环化。由常见的前体二酰基肼13的反应制备生物甾体1,3,4-恶二唑14和1,3,4-噻二唑16分别使用亚硫酰氯和Lawesson试剂。对合成化合物的抗癌研究表明，在C-3芳基环上存在环戊氧基或正丁氧基，在1,2,4-恶二唑的C-5位置上存在哌啶-4-基或三氯甲基是必不可少的。活动。尤其是1,2,4-恶二唑7i和类似物1,3,4-噻二唑16分别显示出对DU145（IC 50：9.3μM）和MDA-MB-231（IC 50：9.2μM）细胞系的显着活性。。
• Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease
  作者：Jinhui Hu、Tingting Pan、Baijiao An、Zhengcunxiao Li、Xingshu Li、Ling Huang

  DOI：10.1016/j.ejmech.2018.12.013

  日期：2019.2

  Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics, we have designed, synthesized and evaluated a series of new clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of AD. In vitro studies demonstrated that some of the molecules processed remarkable inhibitory activity against phosphodiesterase

  考虑到PDE4D抑制和生物金属在阿尔茨海默氏病（AD）疗法中的重要性，我们设计，合成和评估了一系列新的氯喹诺醇-咯利普兰/鲁氟司特杂合体，作为多靶点定向配体用于AD治疗。体外研究表明，某些分子对磷酸二酯酶4D（PDE4D）具有显着的抑制活性，强大的细胞内抗氧化能力，对金属诱导的Aβ聚集的有效抑制作用以及潜在的血脑屏障通透性。化合物7a中展示了在认知和空间记忆显著改善在Aβ 25-35在莫里斯水迷宫测试（MWM）-induce小鼠模型。这些结果表明化合物7a 是一个有前途的多功能候选人，值得进一步研究。